BR112014010139A2 - formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo - Google Patents

formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo

Info

Publication number
BR112014010139A2
BR112014010139A2 BR112014010139A BR112014010139A BR112014010139A2 BR 112014010139 A2 BR112014010139 A2 BR 112014010139A2 BR 112014010139 A BR112014010139 A BR 112014010139A BR 112014010139 A BR112014010139 A BR 112014010139A BR 112014010139 A2 BR112014010139 A2 BR 112014010139A2
Authority
BR
Brazil
Prior art keywords
polypeptide
patient
reducing
pharmaceutical formulation
blood sugar
Prior art date
Application number
BR112014010139A
Other languages
English (en)
Inventor
Weiss Michael
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of BR112014010139A2 publication Critical patent/BR112014010139A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112014010139A 2011-10-27 2012-10-29 formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo BR112014010139A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552246P 2011-10-27 2011-10-27
PCT/US2012/062423 WO2013063572A1 (en) 2011-10-27 2012-10-29 Ultra-concentrated rapid-acting insulin analogue formulations

Publications (1)

Publication Number Publication Date
BR112014010139A2 true BR112014010139A2 (pt) 2017-04-25

Family

ID=48168643

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010139A BR112014010139A2 (pt) 2011-10-27 2012-10-29 formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo

Country Status (10)

Country Link
US (1) US9908925B2 (pt)
EP (1) EP2771026A4 (pt)
JP (1) JP2014533241A (pt)
KR (1) KR20150021011A (pt)
CN (1) CN104010652A (pt)
AU (1) AU2012328407A1 (pt)
BR (1) BR112014010139A2 (pt)
IN (1) IN2014CN03888A (pt)
SG (1) SG11201401835VA (pt)
WO (1) WO2013063572A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590882A1 (ru) * 2012-11-05 2015-09-30 Кейс Вестерн Ризерв Юниверсити Одноцепочечные аналоги инсулина длительного действия
AU2015204491B2 (en) 2014-01-13 2021-01-07 Thermalin Inc. Rapid action insulin formulations and pharmaceutical delivery systems
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
EP3223844A4 (en) * 2014-10-20 2018-08-15 Case Western Reserve University Halogenated insulin analogues of enhanced biological potency
JP6484337B2 (ja) * 2014-11-21 2019-03-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． インスリン受容体部分アゴニスト
WO2016105545A2 (en) * 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
TW201717998A (zh) 2015-08-25 2017-06-01 諾佛 儂迪克股份有限公司 新穎胰島素衍生物及其醫學用途
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
WO2017070617A1 (en) * 2015-10-21 2017-04-27 Case Western Reserve University Diol-modified insulin analogues containing a glucose-regulated conformational switch
KR20180097517A (ko) 2015-12-23 2018-08-31 케이스 웨스턴 리저브 유니버시티 매우 안정된 인슐린 유사체의 중합체 용융물 내 캡슐화
BR112022009510A2 (pt) 2019-12-11 2022-08-16 Novo Nordisk As Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
EP0425482B1 (en) 1988-07-20 1993-08-18 Novo Nordisk A/S Human insulin analogs and preparations containing them
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US20030104981A1 (en) * 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
CN1787833A (zh) * 2003-03-11 2006-06-14 诺沃挪第克公司 包含酸－稳定化胰岛素的药物制备物
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
JP2008510692A (ja) * 2004-08-20 2008-04-10 ノボ ノルディスク アクティーゼルスカブ 薬学的に活性なインスリン受容体調節分子
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
AU2009276346B2 (en) * 2008-07-31 2014-07-03 Case Western Reserve University Halogen-stabilized insulin
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
WO2010080606A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs

Also Published As

Publication number Publication date
CN104010652A (zh) 2014-08-27
KR20150021011A (ko) 2015-02-27
SG11201401835VA (en) 2014-09-26
US9908925B2 (en) 2018-03-06
US20140323398A1 (en) 2014-10-30
IN2014CN03888A (pt) 2015-10-16
NZ624493A (en) 2016-02-26
EP2771026A4 (en) 2015-08-05
AU2012328407A1 (en) 2014-05-22
WO2013063572A1 (en) 2013-05-02
JP2014533241A (ja) 2014-12-11
EP2771026A1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
BR112014010139A2 (pt) formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo
ZA201400616B (en) Methods and devices for drug delivery to ocular tissue using microneedle
DK2641614T3 (da) Farmaceutisk præparat integreret med mikronåle til hudbehandling
EP2532668A4 (en) OPTICALLY ACTIVE 2-HYDROXY-TETRAHYDROTHIA-PYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE IN MEDICAMENT MANUFACTURE
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
HK1246646A1 (zh) 用於治療糖尿病性視網膜病及其他眼科疾病的方法
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
BR112012032948A2 (pt) dispositivos injectores e método de suprimento de solução oftálmica à córnea do olho
WO2011088120A8 (en) Antibody formulation and therapeutic regimens
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
BR112012027545A2 (pt) composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo
BR112013009970A2 (pt) método para determinar uma característica do ritmo circadiano de um paciente.
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
BR112013023743A2 (pt) anticorpo de fator de tecidos humanos e usos do mesmo
EP3628326C0 (en) METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
DK3479863T3 (da) Sammensætninger, fremgangsmåder og artikler indeholdende farmaceutisk nitrogenoxid og regulerede leveringssystemer deraf til patienter
FR2954943B1 (fr) Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
EP2563395A4 (en) TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]